Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Cost Realignment Program by Year
Cost Realignment Program — Cumulative costs attributable to Biopharma ($M) ($M)
Pfizer Cost Realignment Program: $3,200M in FY2025, up 52.4% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K Note 3 — Restructuring Charges & Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cost Realignment Program — Cumulative costs attributable to Biopharma ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,200 | +52.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 2,100 | +211.6% | Form 10-K (filed 2025-02-27) ↗ |
| FY2023 | Dec 31, 2023 | 674 | – | Form 10-K (filed 2024-02-22) ↗ |
Cite this data
StockData. (2026). Pfizer Cost Realignment Program ($M), annual FY2023–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/restruct-cum-realign-bio
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.